Please assess the completion status of the following clinical trial:

Trial Title: Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. - Having voluntarily given informed consent before performing any test that is not part of~   routine care of patients.~2. - Age greater than or equal to 65.~3. - Morphological diagnosis of non-promyelocytic AML according to the WHO criteria.~4. - Newly diagnosed AML.~5. - ECOG performance status \<4.~6. - Ability and willingness to comply with the schedule of study visits.~Exclusion Criteria:~1. - Genetic diagnosis of acute promyelocytic leukemia.~2. - Patients with AML secondary to myelodysplastic syndrome (MDS) or chronic myeloproloferative syndrome who have been previously treated with antileukemic agents~   (hypomethylating or standard chemotherapy). Treatment with hydroxyurea prior to randomization is allowed.~3. - Serum creatinine ≥ 250 mmol / l (≥ 2.5 mg/dL) (unless attributed to AML).~4. - Bilirubin, alkaline phosphatase or ALT \> 5 times the value of the upper limit of normal (unless attributed to AML) .~5. - Presence of an active and/or non controlled pathology different to AML which is severe and life-threatening, that in the investigator's opinion, prevents the subject participation in the study.~6. - Other active concomitant malignancy or whose remission is less than one year from the screening day (except carcinoma in situ).~7. - Presence of any psychiatric illness or medical condition that, in the investigator's opinion, prevents the subject participation in the study.~8. - Life expectancy less than X months.~9. - Inability of the patient or his legal representative to understand and voluntarily sign the informed consent form.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- fludarabine cytarabine (Type: ACTIVE_COMPARATOR): Priming with daily administration of subcutaneous G-CSF (lenograstim or filgrastim 5 mcg /kg / day, days -1, 1 and 2) (not given if hyperleukocytosis\> 25 x 109/l), followed by:~* Oral fludarabine (40 mg/m2/day, days 1 to 5) and subcutaneous cytarabine (75mg/m2/day, days 1 to 5) (FLUGA scheme) (fludarabine and cytarabine only days 1 to 4 if age ≥75 years), OR~* Fludarabine (25 mg/m2/day) and cytarabine (75 mg/m2/day infusion of 6 hours) on their intravenous formulations if the patient is hospitalized (patients with hyperleukocytosis or other unfavourable conditions).~Treatment cycles every 28 days
- Azacitidine (Type: EXPERIMENTAL): Subcutaneous Azacitidine 75 mg/m2/day, days 1 to 7. Treatment cycles every 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).